Funding Opportunity RFA-TR-19-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.

Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, developmental biology, genetics, immunology, neuroscience, pharmacology, physiology, and technology development. In addition to the laboratory experience, the PRAT program provides a structured training environment with extensive career and professional development, mentoring, and networking opportunities planned and supported by the program.

Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)

Notice NOT-DA-19-046 from the NIH Guide for Grants and Contracts

Competitive + Excellent Benefits: AstraZeneca - Cambridge: At AstraZeneca, we turn ideas into life changing medicines. Working here means being entrepreneurial, thinking big and working together Cambridge, Cambridgeshire

Competitive Salary: EMBL: Ensembl Comparative Genomics Project Leader Location Cambridge, Cambridgeshire, England

£30,042 to £39,640 per annum: National Institute of Agricultural Botany (NIAB): We are looking for an enthusiastic and talented bioinformatician/quantitative geneticist to work on the genetics of wheat yellow rust resistance Cambridge, Cambridgeshire

This project will provide the selected candidate with experience and training in plant molecular biology and genetics, generation of transgenic plants, and... $5,185 a month
From Oak Ridge Associated Universities - Fri, 17 May 2019 20:17:03 GMT - View all Madison, WI jobs

Funding Opportunity RFA-RM-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that propose to establish Offices of Sponsored Programs (OSPs) or enhance the services of existing OSPs or similar entities at domestic institutions of higher learning. Program priorities include funding primarily undergraduate institutions with emerging biomedical research and/or undergraduate research training programs.

Notice NOT-OD-19-110 from the NIH Guide for Grants and Contracts

Competitive salary + Pension, Health insurance, Gym, Bonus, Shares: Illumina: You will work on algorithms and methods in bioinformatics, machine learning, signal processing, and develop workflows and programming interfaces. Great Abington, Cambridge

Notice NOT-NS-19-059 from the NIH Guide for Grants and Contracts

Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)

Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)

Funding Opportunity RFA-DA-20-013 from the NIH Guide for Grants and Contracts. NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.

Competitive Salary: EMBL: Scientific Programmer / Bioinformatician Location: Germany (DE)

Notice NOT-GM-19-041 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-20-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs

Funding Opportunity RFA-DA-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs

Funding Opportunity PAR-19-281 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).